Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: Results of the National LymphoCare Study

Peter Martin, Michelle Byrtek, Keith Dawson, Ryan Ziemiecki, Jonathan W. Friedberg, James R Cerhan, Christopher R. Flowers, Brian K. Link

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

BACKGROUND Drug choice and delivered dose of treatment potentially influence outcome in patients treated for follicular lymphoma (FL). Historically, observational studies have evaluated drug choice. The National LymphoCare Study (NLCS) is a prospective, observational study of patients with FL who were enrolled at academic and community practice sites in the United States between 2004 and 2007. In the current study, the authors report on measures of delivered dose and its impact on outcomes for the most common first-line regimens. METHODS All evaluable patients with FL who were treated with initial rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP); or rituximab plus a fludarabine-containing regimen (R-Flu) were included. Associations between baseline factors, choice of treatment, number of cycles received, completion of therapy, and patient outcomes were assessed. RESULTS A total of 646 patients received R-CHOP, 297 received R-CVP, and 222 received R-Flu. Characteristics were similar between the 3 groups with the following exceptions. Patients receiving R-CHOP were more often found to have grade 3 FL and patients receiving R-CVP were older and had higher Follicular Lymphoma International Prognostic Index scores. The majority of patients (80%) received ≥ 5 cycles of treatment. Toxicity, but not disease progression, was commonly cited as the reason for the early discontinuation of treatment (51% vs 6%). Time to retreatment was shorter for patients receiving ≤ 4 cycles, regardless of the treatment regimen used. The number of cycles was associated with overall survival, progression-free survival, and lymphoma-related mortality for patients receiving R-CVP. CONCLUSIONS The majority of patients with FL receiving chemoimmunotherapy in the NLCS completed ≥ 5 cycles of treatment. Strategies to improve dose delivery appear unlikely to impact outcomes, except possibly in patients receiving R-CVP. Although early treatment discontinuation appears to be associated with survival, this analysis does not implicate causality.

Original languageEnglish (US)
Pages (from-to)4129-4136
Number of pages8
JournalCancer
Volume119
Issue number23
DOIs
StatePublished - Dec 1 2013

Fingerprint

Follicular Lymphoma
Vincristine
Prednisone
Cyclophosphamide
Therapeutics
Observational Studies
Retreatment
Survival Analysis
Rituximab
Causality
Pharmaceutical Preparations
Doxorubicin
Disease-Free Survival
Disease Progression
Lymphoma

Keywords

  • chemotherapy
  • completion
  • dose
  • follicular lymphoma
  • intensity
  • rituximab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States : Results of the National LymphoCare Study. / Martin, Peter; Byrtek, Michelle; Dawson, Keith; Ziemiecki, Ryan; Friedberg, Jonathan W.; Cerhan, James R; Flowers, Christopher R.; Link, Brian K.

In: Cancer, Vol. 119, No. 23, 01.12.2013, p. 4129-4136.

Research output: Contribution to journalArticle

Martin, P, Byrtek, M, Dawson, K, Ziemiecki, R, Friedberg, JW, Cerhan, JR, Flowers, CR & Link, BK 2013, 'Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: Results of the National LymphoCare Study', Cancer, vol. 119, no. 23, pp. 4129-4136. https://doi.org/10.1002/cncr.28350
Martin, Peter ; Byrtek, Michelle ; Dawson, Keith ; Ziemiecki, Ryan ; Friedberg, Jonathan W. ; Cerhan, James R ; Flowers, Christopher R. ; Link, Brian K. / Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States : Results of the National LymphoCare Study. In: Cancer. 2013 ; Vol. 119, No. 23. pp. 4129-4136.
@article{544f01a41dbb4da19a44fb0072a9d8b2,
title = "Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: Results of the National LymphoCare Study",
abstract = "BACKGROUND Drug choice and delivered dose of treatment potentially influence outcome in patients treated for follicular lymphoma (FL). Historically, observational studies have evaluated drug choice. The National LymphoCare Study (NLCS) is a prospective, observational study of patients with FL who were enrolled at academic and community practice sites in the United States between 2004 and 2007. In the current study, the authors report on measures of delivered dose and its impact on outcomes for the most common first-line regimens. METHODS All evaluable patients with FL who were treated with initial rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP); or rituximab plus a fludarabine-containing regimen (R-Flu) were included. Associations between baseline factors, choice of treatment, number of cycles received, completion of therapy, and patient outcomes were assessed. RESULTS A total of 646 patients received R-CHOP, 297 received R-CVP, and 222 received R-Flu. Characteristics were similar between the 3 groups with the following exceptions. Patients receiving R-CHOP were more often found to have grade 3 FL and patients receiving R-CVP were older and had higher Follicular Lymphoma International Prognostic Index scores. The majority of patients (80{\%}) received ≥ 5 cycles of treatment. Toxicity, but not disease progression, was commonly cited as the reason for the early discontinuation of treatment (51{\%} vs 6{\%}). Time to retreatment was shorter for patients receiving ≤ 4 cycles, regardless of the treatment regimen used. The number of cycles was associated with overall survival, progression-free survival, and lymphoma-related mortality for patients receiving R-CVP. CONCLUSIONS The majority of patients with FL receiving chemoimmunotherapy in the NLCS completed ≥ 5 cycles of treatment. Strategies to improve dose delivery appear unlikely to impact outcomes, except possibly in patients receiving R-CVP. Although early treatment discontinuation appears to be associated with survival, this analysis does not implicate causality.",
keywords = "chemotherapy, completion, dose, follicular lymphoma, intensity, rituximab",
author = "Peter Martin and Michelle Byrtek and Keith Dawson and Ryan Ziemiecki and Friedberg, {Jonathan W.} and Cerhan, {James R} and Flowers, {Christopher R.} and Link, {Brian K.}",
year = "2013",
month = "12",
day = "1",
doi = "10.1002/cncr.28350",
language = "English (US)",
volume = "119",
pages = "4129--4136",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "23",

}

TY - JOUR

T1 - Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States

T2 - Results of the National LymphoCare Study

AU - Martin, Peter

AU - Byrtek, Michelle

AU - Dawson, Keith

AU - Ziemiecki, Ryan

AU - Friedberg, Jonathan W.

AU - Cerhan, James R

AU - Flowers, Christopher R.

AU - Link, Brian K.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - BACKGROUND Drug choice and delivered dose of treatment potentially influence outcome in patients treated for follicular lymphoma (FL). Historically, observational studies have evaluated drug choice. The National LymphoCare Study (NLCS) is a prospective, observational study of patients with FL who were enrolled at academic and community practice sites in the United States between 2004 and 2007. In the current study, the authors report on measures of delivered dose and its impact on outcomes for the most common first-line regimens. METHODS All evaluable patients with FL who were treated with initial rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP); or rituximab plus a fludarabine-containing regimen (R-Flu) were included. Associations between baseline factors, choice of treatment, number of cycles received, completion of therapy, and patient outcomes were assessed. RESULTS A total of 646 patients received R-CHOP, 297 received R-CVP, and 222 received R-Flu. Characteristics were similar between the 3 groups with the following exceptions. Patients receiving R-CHOP were more often found to have grade 3 FL and patients receiving R-CVP were older and had higher Follicular Lymphoma International Prognostic Index scores. The majority of patients (80%) received ≥ 5 cycles of treatment. Toxicity, but not disease progression, was commonly cited as the reason for the early discontinuation of treatment (51% vs 6%). Time to retreatment was shorter for patients receiving ≤ 4 cycles, regardless of the treatment regimen used. The number of cycles was associated with overall survival, progression-free survival, and lymphoma-related mortality for patients receiving R-CVP. CONCLUSIONS The majority of patients with FL receiving chemoimmunotherapy in the NLCS completed ≥ 5 cycles of treatment. Strategies to improve dose delivery appear unlikely to impact outcomes, except possibly in patients receiving R-CVP. Although early treatment discontinuation appears to be associated with survival, this analysis does not implicate causality.

AB - BACKGROUND Drug choice and delivered dose of treatment potentially influence outcome in patients treated for follicular lymphoma (FL). Historically, observational studies have evaluated drug choice. The National LymphoCare Study (NLCS) is a prospective, observational study of patients with FL who were enrolled at academic and community practice sites in the United States between 2004 and 2007. In the current study, the authors report on measures of delivered dose and its impact on outcomes for the most common first-line regimens. METHODS All evaluable patients with FL who were treated with initial rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP); or rituximab plus a fludarabine-containing regimen (R-Flu) were included. Associations between baseline factors, choice of treatment, number of cycles received, completion of therapy, and patient outcomes were assessed. RESULTS A total of 646 patients received R-CHOP, 297 received R-CVP, and 222 received R-Flu. Characteristics were similar between the 3 groups with the following exceptions. Patients receiving R-CHOP were more often found to have grade 3 FL and patients receiving R-CVP were older and had higher Follicular Lymphoma International Prognostic Index scores. The majority of patients (80%) received ≥ 5 cycles of treatment. Toxicity, but not disease progression, was commonly cited as the reason for the early discontinuation of treatment (51% vs 6%). Time to retreatment was shorter for patients receiving ≤ 4 cycles, regardless of the treatment regimen used. The number of cycles was associated with overall survival, progression-free survival, and lymphoma-related mortality for patients receiving R-CVP. CONCLUSIONS The majority of patients with FL receiving chemoimmunotherapy in the NLCS completed ≥ 5 cycles of treatment. Strategies to improve dose delivery appear unlikely to impact outcomes, except possibly in patients receiving R-CVP. Although early treatment discontinuation appears to be associated with survival, this analysis does not implicate causality.

KW - chemotherapy

KW - completion

KW - dose

KW - follicular lymphoma

KW - intensity

KW - rituximab

UR - http://www.scopus.com/inward/record.url?scp=84888007764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888007764&partnerID=8YFLogxK

U2 - 10.1002/cncr.28350

DO - 10.1002/cncr.28350

M3 - Article

C2 - 24006156

AN - SCOPUS:84888007764

VL - 119

SP - 4129

EP - 4136

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 23

ER -